A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/517 (2006.01) A61K 31/167 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2622136
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
L'invention concerne une méthode de traitement du cancer chez un sujet nécessitant un tel traitement, consistant à administrer au sujet une première quantité d'un inhibiteur de la histone déacétylase (HDAC), tel que l'acide suberoylanilide hydroxamique (SAHA) ou un sel ou hydrate acceptable sur le plan pharmaceutique de celui-ci et une seconde quantité d'un ou plusieurs agents anti-cancer, notamment l'Erlotinibe. L'inhibiteur HDAC et l'agent anti-cancer peuvent être administrés de manière à comprendre des quantités efficaces sur le plan thérapeutique. Dans divers modes de réalisation, l'effet de l'inhibiteur HDAC et de l'agent anti-cancer peuvent s'additionner ou être synergiques.
Bunn Paul
Deutsch Paul J.
Frankel Stanley R.
Randolph Sophia
Richon Victoria M.
Gowling Lafleur Henderson Llp
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
The Regents Of The University Of Colorado
LandOfFree
Methods of using saha and erlotinib for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using saha and erlotinib for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using saha and erlotinib for treating cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1722350